Sumitomo to Transfer Antitumor Antibiotic Sales to Nippon Kayaku

Sumitomo Pharmaceuticals has announced that it has signed a memorandum to transfer sales of its proprietary antitumor drug Calsed to Nippon Kayaku. In addition, the two companies will collaborate in post-marketing surveillance studies. Calsed, an anthracycline antitumor agent, has been widely used in the treatments of small-cell and non-small-cell lung cancers since its release in December 2002.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9186)